Member Articles

Best in Biotech? Global Blood Therapeutics’ Promising Treatment for Sickle Cell Anemia

by

We remain impressed with the depth of research conducted over a wide host of disease states. Though a molecule may appear to hold significant promise in the pre-clinical phase, we have often witnessed the unique ability of the human body to react to various treatments. Often an unwanted side effect can torpedo a treatment, thus relegating millions of dollars of research obsolete. However, if a promising molecule is brought to market, the payoff is often well worth the effort. Our goal is to sift through the various clinical data to unearth the most promising treatments with the understanding that nothing is assured until the FDA authorizes the product for marketing in the US. We believe we have identified a promising … Read more

The Asset Sales at Teva Have Begun

by

Image Source: Teva We continue to watch the implosion of Teva with some interest; the company was once a Best Ideas Newsletter portfolio idea thanks to its strong ability to generate a copious amount of free cash flow. However, Teva made the classic mistake of purchasing a company that operates in a highly-commoditized industry at a market top while loading up the balance sheet with an enormous amount of debt at the precise time the favorable industry dynamics began transitioning to a headwind. Let’s review the company’s progress for signs of a turnaround. By Alexander J. Poulos Management Shakeup Corporate leadership remains a challenging field where a critical misstep can often end a once-promising career. The management team of Teva … Read more

Our Reports on Stocks in the Book Publishing Industry

by

Structure of the Book Publishing Industry Firms in the book publishing industry compete primarily on the basis of quality and price. Rivals include numerous book, ebook, textbook, library, reference material, and Internet resellers. Industry constituents can carve out advantages by offering a comprehensive offering, as in the case of Scholastic’s suite of reading intervention products and services. Still, firms are subject to rapid changes in consumer preferences, especially within the ebook market, which is just beginning to take shape. We’re neutral on the group’s structure. Please click on a company name below to view the corresponding equity report. << Our Dividend Reports

Dividend Increases/Decreases for the Week Ending September 15

by

Below we provide a list of firms that raised/lowered their dividends during the week ending September 15. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week American Tower (AMT): now $0.66 per share quarterly dividend, was $0.64. Argan (AGX): now $1.00 per share annual dividend, was $0.70. Broadridge Financial Solutions (BR): now $0.365 per share quarterly dividend, was $0.33. Curtis-Wright (CW): now $0.15 per share quarterly dividend, was $0.13. Entravision (EVC): now $0.05 per share quarterly dividend, was $0.03125. Farmers & Merchants Bancorp (FMAO): now $0.26 per share quarterly dividend, was $0.25. … Read more

Apple: Innovation Versus Improvements

by

Image Source: Valuentum Apple’s 2017 iPhone event took place September 12, and it was one of the most highly anticipated of such events. Let’s take a look at what improvements are being made and how they might impact our thesis on the tech giant. By Kris Rosemann Newsletter portfolio holding Apple (AAPL) has made a spectacle of its annual iPhone event in which it reveals the most recent improvements it makes to its flagship product, as well as other new products and features across its lineup. This year’s event, which took place September 12, was one of the most highly-anticipated events in the iPhone’s 10-year history, due in large part to the anticipation surrounding the iPhone X (iPhone 10 in … Read more

Upadacitinib Posts Impressive Data for AbbVie

by

Image Source: AbbVie In the pharmaceutical realm, the productivity of the clinical pipeline is essential to replace the loss of revenue due to an expiration of the patent life of a product. AbbVie is facing the monumental task of having to diversify away from the top-selling pharmaceutical product in the world with little in the way of assurances the transition will be a success. We are pleased with the recent data release on Upadacitinib as we view the molecule as AbbVie’s top R&D product. By Alexander J. Poulos Upadacitinib in Rheumatoid Arthritis AbbVie (ABBV) believes it can successfully transition its portfolio from top-selling product Humira over to its next-generation treatment. AbbVie’s Upadacitinib belongs to the novel class of JAK-1 inhibitors, … Read more

Earnings Snapshot: Cracker Barrel’s Hidden 5%+ Dividend Yield

by

Cracker Barrel is holding its share-price uptrend nicely. The company is one of our favorite restaurants thanks in part to its differentiated niche and country store concept. Special dividend payouts make it a hidden income gem, in our view. By Brian Nelson, CFA Here’s what we wrote last May, “Cracker Barrel Hits the Trifecta!:” Cracker Barrel’s (CBRL) store-within-a-restaurant concept is one of the best revenue-generators per square foot around, and it is run by a management team that knows the importance of the dividend to income investors. We continue to believe it is a great fit for the Dividend Growth Newsletter portfolio and an often overlooked one in light of its preponderance of special dividends that often fly under the … Read more

Target, Kroger Launch Counterattack on Amazon-Whole Foods; Industry Earnings to Shrink

by

Image Source: Valuentum The pricing war has begun, but it may take years before we see the final effects. Only the strongest may come out ahead, and only those already focusing on giving customers the very best value proposition at the lowest prices may retain share. By Brian Nelson, CFA The grocery store business is now on a path of significant change in the wake of news that Amazon (AMZN) would acquire upscale organic grocer Whole Foods (WFM). The online retailing giant has wasted little time in resetting the product pricing environment at Whole Foods, and we expect that other grocers will have to follow. The group had already been on high alert given recent language from Kroger (KR), suggesting … Read more